Exploiting cytokines in adoptive T-cell therapy of cancer

Immunotherapy

Volumn 7, Issue 5, 2015, Pages 573-584

  Petrozziello, Elisabetta ^a   Sturmheit, Tabea ^a   Mondino, Anna ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

adoptive T cell therapy; common chain cytokines; hematological malignancies; innate and adaptive immune responses; proinflammatory cytokines; solid tumor; T cell differentiation; T cell homing; tumor microenvironment

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; INTERLEUKIN 7; T LYMPHOCYTE RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE T CELL THERAPY; CANCER IMMUNOTHERAPY; CELL THERAPY; CLINICAL TRIAL (TOPIC); ENGRAFTMENT; GENETIC ENGINEERING; HUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; AUTOGRAFT; CELLULAR IMMUNITY; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; PROCEDURES; TRANSPLANTATION;

ANIMALS; AUTOGRAFTS; CYTOKINES; HUMANS; IMMUNITY, CELLULAR; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES;

EID: 84931047475     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.15.19     Document Type: Review

References (89)

1. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12(4), 269-281 (2012).
2. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu. Rev. Med. 65, 333-347 (2014).
3. Gattinoni L, Powell DJ Jr, Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat. Rev. Immunol. 6(5), 383-393 (2006).
4. Gattinoni L, Zhong XS, Palmer DC et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15(7), 808-813 (2009).
5. Gattinoni L, Lugli E, Ji Y et al. A human memory T cell subset with stem cell-like properties. Nat. Med. 17(10), 1290-1297 (2011).
6. Cieri N, Camisa B, Cocchiarella F et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 121(4), 573-584 (2013).
7. Besser MJ, Shapira-Frommer R, Treves AJ et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor-infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16(9), 2646-2655 (2010).
8. Dudley ME, Gross CA, Langhan MM et al. CD8+ enriched young tumor-infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 16(24), 6122-6131 (2010).
9. Huang J, Kerstann KW, Ahmadzadeh M et al. Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy. J. Immunol. 176(12), 7726-7735 (2006).
10. Zhou J, Shen X, Huang J, Hodes RJ, Rosenberg SA, Robbins PF. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy. J. Immunol. 175(10), 7046-7052 (2005).
11. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011).
12. Louis CU, Savoldo B, Dotti G et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118(23), 6050-6056 (2011).
13. Xu Y, Zhang M, Ramos CA et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR. CD19-T cells and are preserved by IL-7 and IL-15. Blood 123(24), 3750-3759 (2014).
14. Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111(1), 229-235 (2008).
15. Perna SK, De Angelis B, Pagliara D et al. Interleukin 15 provides relief to CTLs from regulatory T cell-mediated inhibition: implications for adoptive T cell-based therapies for lymphoma. Clin. Cancer Res. 19(1), 106-117 (2013).
16. Perna SK, Pagliara D, Mahendravada A et al. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin. Cancer Res. 20(1), 131-139 (2014).
17. Rosenberg SA. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192(12), 5451-5458 (2014).
18. Zhou J, Nagarkatti P, Zhong Y, Nagarkatti M. Characterization of T-cell memory phenotype after in vitro expansion of tumor-infiltrating lymphocytes from melanoma patients. Anticancer Res. 31(12), 4099-4109 (2011).
19. Neeson P, Shin A, Tainton KM et al. Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype. Gene Ther. 17(9), 1105-1116 (2010).
20. Yang S, Gattinoni L, Liu F et al. In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. Cancer Immunol. Immunother. 60(5), 739-749 (2011).
21. Boyman O, Krieg C, Homann D, Sprent J. Homeostatic maintenance of T cells and natural killer cells. Cell Mol. Life Sci. 69(10), 1597-1608 (2012).
22. Lundstrom W, Fewkes NM, Mackall CL. IL-7 in human health and disease. Semin. Immunol. 24(3), 218-224 (2012).
23. Liu S, Riley J, Rosenberg S, Parkhurst M. Comparison of common gamma-chain cytokines, interleukin-2, interleukin-7, and interleukin-15 for the in vitro generation of human tumor-reactive T lymphocytes for adoptive cell transfer therapy. J. Immunother. 29(3), 284-293 (2006).
24. Caserta S, Alessi P, Basso V, Mondino A. IL-7 is superior to IL-2 for ex vivo expansion of tumour-specific CD4 (+) T cells. Eur. J. Immunol. 40(2), 470-479 (2010).
25. Cavalieri S, Cazzaniga S, Geuna M et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood 102(2), 497-505 (2003).
26. Hinrichs CS, Spolski R, Paulos CM et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111(11), 5326-5333 (2008).
27. Judge AD, Zhang X, Fujii H, Surh CD, Sprent J. Interleukin 15 controls both proliferation and survival of a subset of memory-phenotype CD8 (+) T cells. J. Exp. Med. 196(7), 935-946 (2002).
28. Klebanoff CA, Finkelstein SE, Surman DR et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl Acad. Sci. USA 101(7), 1969-1974 (2004).
29. Lu J, Giuntoli RL 2nd, Omiya R, Kobayashi H, Kennedy R, Celis E. Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. Clin. Cancer Res. 8(12), 3877-3884 (2002).
30. Alcantar-Orozco EM, Gornall H, Baldan V, Hawkins RE, Gilham DE. Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum. Gene Ther. Methods 24(5), 310-320 (2013).
31. Spolski R, Leonard WJ. Interleukin-21: a double-edged sword with therapeutic potential. Nat. Rev. Drug Discov. 13(5), 379-395 (2014).
32. Elsaesser H, Sauer K, Brooks DG. IL-21 is required to control chronic viral infection. Science 324(5934), 1569-1572 (2009).
33. Yi JS, Du M, Zajac AJ. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324(5934), 1572-1576 (2009).
34. Frohlich A, Kisielow J, Schmitz I et al. IL-21R on T cells is critical for sustained functionality and control of chronic viral infection. Science 324(5934), 1576-1580 (2009).
35. Zeng R, Spolski R, Finkelstein SE et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J. Exp. Med. 201(1), 139-148 (2005).
36. Santegoets SJ, Turksma AW, Suhoski MM et al. IL-21 promotes the expansion of CD27+ CD28+ tumor-infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells. J. Transl. Med. 11, 37 (2013).
37. Pollack SM, Jones RL, Farrar EA et al. Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8 (+) T cells. J. Immunother. Cancer 2(1), 36 (2014).
38. Kaneko S, Mastaglio S, Bondanza A et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood 113(5), 1006-1015 (2009).
39. Gomez-Eerland R, Nuijen B, Heemskerk B et al. Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype. Hum. Gene Ther. Methods 25(5), 277-287 (2014).
40. Pouw N, Treffers-Westerlaken E, Kraan J et al. Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells. Cancer Immunol. Immunother. 59(6), 921-931 (2010).
41. Alves NL, Arosa FA, Van Lier RA. IL-21 sustains CD28 expression on IL-15-activated human naive CD8+ T cells. J. Immunol. 175(2), 755-762 (2005).
42. Huarte E, Fisher J, Turk MJ et al. Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma. Cancer Lett. 285(1), 80-88 (2009).
43. Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J. Immunol. 184(1), 452-465 (2010).
44. Kishida T, Asada H, Itokawa Y et al. Interleukin (IL)-21 and IL-15 genetic transfer synergistically augments therapeutic antitumor immunity and promotes regression of metastatic lymphoma. Mol. Ther. 8(4), 552-558 (2003).
45. Pouw N, Treffers-Westerlaken E, Mondino A, Lamers C, Debets R. TCR gene-engineered T cell: limited T cell activation and combined use of IL-15 and IL-21 ensure minimal differentiation and maximal antigen-specificity. Mol. Immunol. 47(7-8), 1411-1420 (2010).
46. Lee JB, Lee KA, Chang J. Phenotypic changes induced by IL-12 priming regulate effector and memory CD8 T cell differentiation. Int. Immunol. 19(9), 1039-1048 (2007).
47. Ye Z, Xu S, Moyana T, Yang J, Xiang J. Defect of CD8+ memory T cells developed in absence of IL-12 priming for secondary expansion. Cell Mol. Immunol. 5(2), 147-152 (2008).
48. Yang S, Ji Y, Gattinoni L et al. Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunol. Immunother. 62(4), 727-736 (2012).
49. Smith FO, Downey SG, Klapper JA et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin. Cancer Res. 14(17), 5610-5618 (2008).
50. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005).
51. Radvanyi LG, Bernatchez C, Zhang M et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 18(24), 6758-6770 (2012).
52. Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233-5239 (2008).
53. Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917-924 (2011).
54. Chapuis AG, Thompson JA, Margolin KA et al. Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc. Natl Acad. Sci. USA 109(12), 4592-4597 (2012).
55. Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee C. Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS ONE 4(3), e4749 (2009).
56. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 107(6), 2409-2414 (2006).
57. Sim GC, Martin-Orozco N, Jin L et al. IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. J. Clin. Invest. 124(1), 99-110 (2014).
58. Yao X, Ahmadzadeh M, Lu YC et al. Levels of peripheral CD4 (+)FoxP3 (+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119(24), 5688-5696 (2012).
59. Colombetti S, Levy F, Chapatte L. IL-7 adjuvant treatment enhances long-term tumor-antigen-specific CD8+ T-cell responses after immunization with recombinant lentivector. Blood 113(26), 6629-6637 (2009).
60. Murphy WJ, Back TC, Conlon KC et al. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J. Clin. Invest. 92(4), 1918-1924 (1993).
61. Sportes C, Babb RR, Krumlauf MC et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin. Cancer Res. 16(2), 727-735 (2010).
62. Rosenberg SA, Sportes C, Ahmadzadeh M et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J. Immunother. 29(3), 313-319 (2006).
63. Dudley AC. Tumor endothelial cells. Cold Spring Harb. Perspect. Med. 2(3), a006536 (2012).
64. Motz GT, Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11(10), 702-711 (2011).
65. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 279(5349), 377-380 (1998).
66. Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18(11), 1185-1190 (2000).
67. Curnis F, Gasparri A, Sacchi A, Cattaneo A, Magni F, Corti A. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res. 65(7), 2906-2913 (2005).
68. Curnis F, Arrigoni G, Sacchi A et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res. 62(3), 867-874 (2002).
69. Pasqualini R, Koivunen E, Kain R et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 60(3), 722-727 (2000).
70. Sacchi A, Gasparri A, Curnis F, Bellone M, Corti A. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin. Cancer Res. 64(19), 7150-7155 (2004).
71. Bertilaccio MT, Grioni M, Sutherland BW et al. Vasculature-targeted tumor necrosis factor-alpha increases the therapeutic index of doxorubicin against prostate cancer. Prostate 68(10), 1105-1115 (2008).
72. Gregorc V, Zucali PA, Santoro A et al. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. J. Clin. Oncol. 28(15), 2604-2611 (2010).
73. Calcinotto A, Grioni M, Jachetti E et al. Targeting TNF-alpha to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J. Immunol. 188(6), 2687-2694 (2012).
74. Johansson A, Hamzah J, Payne CJ, Ganss R. Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc. Natl Acad. Sci. USA 109(20), 7841-7846 (2011).
75. Stauss HJ, Morris EC. Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. Gene Ther. 20(11), 1029-1032 (2013).
76. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med. 4(4), 408-414 (1998).
77. List T, Neri D. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin. Pharmacol. 5, 29-45 (2013).
78. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev. 257(1), 83-90 (2014).
79. Kerkar SP, Leonardi AJ, Van Panhuys N et al. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol. Ther. 21(7), 1369-1377 (2013).
80. Tugues S, Burkhard SH, Ohs I et al. New insights into IL- 12-mediated tumor suppression. Cell Death Differ. 22(2), 237-246 (2015).
81. Coughlin CM, Salhany KE, Wysocka M et al. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101(6), 1441-1452 (1998).
82. Kerkar SP, Muranski P, Kaiser A et al. Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70(17), 6725-6734 (2010).
83. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71(17), 5697-5706 (2011).
84. Pegram HJ, Lee JC, Hayman EG et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18), 4133-4141 (2012).
85. Liu RB, Engels B, Schreiber K et al. IL-15 in tumor microenvironment causes rejection of large established tumors by T cells in a noncognate T cell receptor-dependent manner. Proc. Natl Acad. Sci. USA 110(20), 8158-8163 (2013).
86. Hoyos V, Savoldo B, Quintarelli C et al. Engineering CD19- specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24(6), 1160-1170 (2010).
87. Raue HP, Beadling C, Haun J, Slifka MK. Cytokine-mediated programmed proliferation of virus-specific CD8 (+) memory T cells. Immunity 38(1), 131-139 (2013).
88. Richer MJ, Nolz JC, Harty JT. Pathogen-specific inflammatory milieux tune the antigen sensitivity of CD8 (+) T cells by enhancing T cell receptor signaling. Immunity 38(1), 140-152 (2013).
89. Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. CAR T cells: driving the road from the laboratory to the clinic. Immunol. Rev. 257(1), 91-106 (2013).